A. Sánchez-Hernandez

发表

Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation

C. García-Girón, J. Bosch-Barrera, M. Provencio, 2022, Cancers.

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer

R. Herbst, S. Dakhil, D. Camidge, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer.

G. De Velasco, D. Olmos, D. Lorente, 2021, European urology.

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden

B. Massuti, V. Calvo, M. Provencio, 2022, JAMA oncology.

Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials

W. Edenfield, S. Morris, Y. Pritchett, 2021, Cancer medicine.

Clinical impact of delays in the management of lung cancer patients in the last decade: systematic review

E. Fernández Martín, M. Guirado, A. Sanchez-Hernandez, 2022, Clinical and Translational Oncology.

Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.

J. Carles, M. Climent, B. Mellado, 2012, Critical reviews in oncology/hematology.

Cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report

E. Enrique, J. Castelló, I. Raducan, 2022, Clinical and Molecular Allergy.

Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base

E. Gallardo, J. Maroto, J. Aparicio, 2014, Clinical and Translational Oncology.

Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial

J. Espinàs, M. Navarro, J M Borras, 2001, BMJ : British Medical Journal.

Geriatric assessment in clinical practice for patients with stage IV non‐small‐cell lung cancer: The Grup de Investigació I Divulgació Oncològica experience

F. Aparisi, O. Juan-Vidal, J. García-Sánchez, 2018, European journal of cancer care.

A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial.

M. Climent, E. Esteban, A. Font, 2022, European journal of cancer.

Quality indicators and excellence requirements for a multidisciplinary lung cancer tumor board by the Spanish Lung Cancer Group

A. Gómez-Caamaño, M. Guirado, L. Pijuan, 2021, Clinical and Translational Oncology.

Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: a multi-center phase II study.

M. Lázaro, V. Giner, Ó. Juan, 2014, Anticancer research.

Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non-Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial.

J. Muñoz-Langa, V. Giner, Ó. Juan, 2015, Clinical lung cancer.

Randomized phase II study of docetaxel (D) + abiraterone acetate (AA) versus D after disease progression to first-line AA in metastatic castration-resistant prostate cancer (mCRPC): ABIDO-SOGUG Trial.

B. Mellado, E. Esteban, A. Font, 2020 .

Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program

E. Esteban, D. Castellano, R. Luque, 2014, Expert opinion on drug safety.

Cutaneous Reaction With Ifosfamide Plus Mesna. A Desensitization Challenge: A Case Report

I. Raducan, A. Sánchez-Hernandez, A. Germán-Sánchez, 2022 .

Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.

C. García-Girón, J. Bosch-Barrera, M. Provencio, 2021, European journal of cancer.